Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

BAY 94-9172 (Florbetaben)

Method of Measurement (Pre-analytical Tools)
Blood/Plasma
Imaging
Biomarker Measured
Amyloid
Use
Monitoring
Pharmacodynamic/response
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

To examine whether brain amyloid plaque load, which will be measured with positron emission tomography and x-ray computed tomography brain imaging using Florbetaben from Bayer, varies as a function of change in plasma levels of amyloid beta.

Target Population/ Population Being Studied

Cognitively Normal Older Adults, Older Adults With Mild Cognitive Impairment, and Older Adults With Alzheimer's Disease. All must be current Washington Heights-Inwood Community Aging Project (WHICAP) participant Age 65 or older Residing in the community of Washington-Heights/Inwood/Hamilton Heights

Length of Current Trial
3 years
Number of Trial Participants

161

Estimated Trial Completion
January 2029
What is Required from Patients

injection of radioactive tracers, mild discomfort, x-ray, blood draw in clinic visit

What is Required from the Health System

PET technician, PET scanner, dyes, x-ray, phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

New York State Psychiatric Institute; Bayer; National Institute on Aging (NIA)

“Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172.” ClinicalTrials.gov. Accessed October 10, 2019. https://clinicaltrials.gov/ct2/show/NCT01222351?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=5&rank=43